Abstract
The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
Original language | English |
---|---|
Publication status | Published - 2006 |